SEC Form 4 · accession 0001209191-17-003809
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Santosh Vetticaden
Officer — Interim CEO
Period of report
Jan 12, 2017
Accepted (ET)
Jan 17, 2017 · 10:40 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $10.39 | Jan 12, 2017 | A | 30,000 | A | — | Jan 12, 2027 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The option vests in 48 equal monthly installments and will be fully vested and exercisable on January 12, 2021.